Omega Diagnostics Group PLC (GB:CNSL)
LSE:CNSL
Want to see GB:CNSL full AI Analyst Report?
CNSL Stock Chart & Stats
2.30 p
-0.05 p(-1.67%)
At close: 4:00 PM EST
2.30 p
-0.05 p(-1.67%)
Day’s Range― - ―
52-Week Range1.70 p - 4.33 p
Previous CloseN/A
Volume6.91K
Average Volume (3M)353.57K
Market Cap
£4.28M
Enterprise Value1.16M
Total Cash (Recent Filing)£3.59M
Total Debt (Recent Filing)£237.00K
Price to Earnings (P/E)3.1
Beta0.73
Next Earnings
Jul 21, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding237,950,650
10 Day Avg. Volume111,535
30 Day Avg. Volume353,573
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.87
P/FCF Ratio-51.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Consumables & CDMO RevenueOmega’s core business sells IVD test kits, reagents and consumables and also provides contract development and manufacturing services. Recurring consumable demand and CDMO contracts create durable revenue streams, customer stickiness and utilization that support stable sales and margin visibility over months.
Low Leverage And Reasonable ROEA very low debt load gives Omega financial flexibility to fund operations, absorb short-term shocks, and invest selectively without heavy interest burden. A ~13.7% ROE indicates the business can generate respectable returns on equity, supporting long-term shareholder value and resilience during cyclical pressure.
High Gross And Positive Net MarginHigh gross margins reflect favorable product economics and pricing power in diagnostics consumables. Combined with a positive net margin, this indicates the underlying product mix can be profitable and supports enduring margin potential if operating efficiencies are improved and top-line stabilizes.
Bears Say
Weak Cash GenerationSeverely negative free cash flow growth and poor cash conversion signal structural cash-generation weakness. This constrains funding for working capital, R&D and capex, raises liquidity risk, and may force reliance on external financing or equity, limiting strategic flexibility over coming months.
Declining Revenue TrendSustained negative revenue growth reduces scale benefits and pressures gross margins and fixed-cost absorption. Ongoing top-line contraction suggests demand weakness or competitive erosion, making it harder to invest in product development and sales, and increasing operational leverage risk over the medium term.
Negative Operating (EBIT) MarginA negative EBIT margin shows core operations are not covering operating costs, pointing to structural inefficiencies or high fixed costs. This undermines sustainable profitability, increases dependence on non-operating items to report net profits, and requires operational fixes to restore durable earnings power.
Omega Diagnostics News
CNSL FAQ
What was Omega Diagnostics Group PLC’s price range in the past 12 months?
Omega Diagnostics Group PLC lowest share price was 1.70 p and its highest was 4.33 p in the past 12 months.
What is Omega Diagnostics Group PLC’s market cap?
Omega Diagnostics Group PLC’s market cap is £4.28M.
When is Omega Diagnostics Group PLC’s upcoming earnings report date?
Omega Diagnostics Group PLC’s upcoming earnings report date is Jul 21, 2026 which is in 40 days.
How were Omega Diagnostics Group PLC’s earnings last quarter?
Omega Diagnostics Group PLC released its earnings results on Nov 10, 2025. The company reported 0 p earnings per share for the quarter, the consensus estimate of N/A by 0 p.
Is Omega Diagnostics Group PLC overvalued?
According to Wall Street analysts Omega Diagnostics Group PLC’s price is currently Overvalued.
Does Omega Diagnostics Group PLC pay dividends?
Omega Diagnostics Group PLC does not currently pay dividends.
What is Omega Diagnostics Group PLC’s EPS estimate?
Omega Diagnostics Group PLC’s EPS estimate is >-0.01.
How many shares outstanding does Omega Diagnostics Group PLC have?
Omega Diagnostics Group PLC has 237,950,650 shares outstanding.
What happened to Omega Diagnostics Group PLC’s price movement after its last earnings report?
Omega Diagnostics Group PLC reported an EPS of 0 p in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -15.094%.
Which hedge fund is a major shareholder of Omega Diagnostics Group PLC?
Currently, no hedge funds are holding shares in GB:CNSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Omega Diagnostics Group PLC
Established in 1987 and headquartered in London, UK, Cambridge Nutritional Sciences plc (formerly Omega Diagnostics Group PLC until its name change in September 2023) is a specialist in the development, manufacturing, and supply of medical diagnostic products. The company primarily operates within the food sensitivity testing market, creating and producing "Foodprint" branded kits designed to detect immune reactions to food. Beyond manufacturing, it provides clinical analysis services directly to the public, clinics, and healthcare professionals, and also offers the "Food Detective" consumer food test. Its diverse client base includes government entities, private hospitals, reference laboratories, nutritionists, naturopaths, and other medical practitioners. Cambridge Nutritional Sciences plc boasts a global presence, serving markets across the United Kingdom, continental Europe, North, South, and Central America, India, various other Asian countries and the Far East, Africa, and the Middle East.
Technical Analysis
Advanced Medical Solutions
―
EKF Diagnostics Holdings
―
IXICO plc
―
Tristel
―
Abingdon Health PLC
―
Options Prices
Currently, No data available
---